The FDA on July 18, 2018 expanded the indication for KISQALI® in combination with an Aromatase Inhibitor for pre and perimenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy. KISQALI® is a product of Novartis Pharmaceuticals Corporation.
Bottom Ad
Advertisement
Subscribe
